AAPL339.96+4.04 (+1.20%) ▲|ABBV264.10-1.02 (-0.38%) ▼|ABT101.07+0.00 (+0.00%) ▲|ACN177.34-0.07 (-0.04%) ▼|ADBE236.16-2.77 (-1.16%) ▼|AMAT483.81+9.56 (+2.02%) ▲|AMD629.73+0.47 (+0.07%) ▲|AMGN411.56+5.52 (+1.36%) ▲|AMT168.51+1.25 (+0.75%) ▲|AMZN249.96+0.58 (+0.23%) ▲|AVGO352.84+2.48 (+0.71%) ▲|AXP309.33+3.67 (+1.20%) ▲|BA199.65+2.85 (+1.45%) ▲|BAC56.53+0.50 (+0.88%) ▲|BKNG163.15+5.74 (+3.64%) ▲|BLK1,082.04+8.59 (+0.80%) ▲|BMY62.27+0.77 (+1.25%) ▲|BNY149.64-0.55 (-0.37%) ▼|BRK-B505.03-0.15 (-0.03%) ▼|C134.15+2.05 (+1.55%) ▲|CAT816.61+11.36 (+1.41%) ▲|CL85.77+0.45 (+0.53%) ▲|CMCSA21.69-0.44 (-1.99%) ▼|COF200.71+4.10 (+2.08%) ▲|COP127.25-2.09 (-1.62%) ▼|COST920.94+24.46 (+2.73%) ▲|CRM234.66-3.57 (-1.50%) ▼|CSCO107.57+0.60 (+0.56%) ▲|CVS88.03+2.98 (+3.50%) ▲|CVX203.73-1.93 (-0.94%) ▼|DE684.50-10.44 (-1.50%) ▼|DHR223.94+0.17 (+0.08%) ▲|DIS105.48-0.09 (-0.08%) ▼|DUK113.02-0.22 (-0.19%) ▼|EMR158.61+2.47 (+1.58%) ▲|FDX284.36+4.82 (+1.72%) ▲|GD337.60+1.31 (+0.39%) ▲|GE327.10+7.32 (+2.29%) ▲|GEV953.04-2.00 (-0.21%) ▼|GILD149.24-0.45 (-0.30%) ▼|GM82.88+2.31 (+2.87%) ▲|GOOG340.78+1.77 (+0.52%) ▲|GOOGL343.94+1.58 (+0.46%) ▲|GS930.99+7.70 (+0.83%) ▲|HD294.34+2.16 (+0.74%) ▲|HON212.37+0.58 (+0.27%) ▲|IBM226.56-0.50 (-0.22%) ▼|INTC124.44-2.95 (-2.32%) ▼|INTU275.79-1.34 (-0.48%) ▼|ISRG402.44+2.92 (+0.73%) ▲|JNJ269.82-0.86 (-0.32%) ▼|JPM341.75+3.19 (+0.94%) ▲|KO87.99-0.11 (-0.12%) ▼|LIN469.20+1.06 (+0.23%) ▲|LLY1,172.43-9.46 (-0.80%) ▼|LMT517.46-6.24 (-1.19%) ▼|LOW189.01+0.52 (+0.28%) ▲|LRCX314.70+7.54 (+2.45%) ▲|MA567.68+1.60 (+0.28%) ▲|MCD237.35+0.33 (+0.14%) ▲|MDLZ60.20-0.67 (-1.09%) ▼|MDT88.38+0.59 (+0.67%) ▲|META750.89-26.70 (-3.43%) ▼|MMM169.83+2.31 (+1.38%) ▲|MO68.66-0.22 (-0.32%) ▼|MRK148.23+0.25 (+0.17%) ▲|MS196.44+0.12 (+0.06%) ▲|MSFT516.65+18.72 (+3.76%) ▲|MU1,082.86+2.33 (+0.22%) ▲|NEE75.94+0.32 (+0.42%) ▲|NFLX71.12-0.61 (-0.84%) ▼|NKE35.90-0.10 (-0.26%) ▼|NOW136.77-1.01 (-0.73%) ▼|NVDA224.82+0.24 (+0.11%) ▲|ORCL138.45-1.10 (-0.78%) ▼|PEP128.17+0.02 (+0.02%) ▲|PFE28.39-0.03 (-0.09%) ▼|PG145.83+0.15 (+0.10%) ▲|PLTR191.89-0.70 (-0.36%) ▼|PM189.20-2.30 (-1.20%) ▼|QCOM204.75+10.49 (+5.40%) ▲|RTX188.32-0.29 (-0.15%) ▼|SBUX94.35+0.70 (+0.74%) ▲|SCHW99.77+0.28 (+0.28%) ▲|SO82.66-0.23 (-0.28%) ▼|SPG205.18+0.48 (+0.23%) ▲|T25.32-0.13 (-0.50%) ▼|TMO670.32-8.07 (-1.19%) ▼|TMUS166.22+0.87 (+0.53%) ▲|TSLA373.23-4.71 (-1.25%) ▼|TXN277.00+6.35 (+2.35%) ▲|UBER69.19-0.03 (-0.04%) ▼|UNH377.15+2.14 (+0.57%) ▲|UNP273.40-0.68 (-0.25%) ▼|UPS93.03+0.98 (+1.06%) ▲|USB59.32+0.92 (+1.58%) ▲|V367.57-0.42 (-0.11%) ▼|VZ46.95-0.38 (-0.79%) ▼|WFC82.67+0.49 (+0.60%) ▲|WMT107.93+0.34 (+0.32%) ▲|XOM160.19-1.95 (-1.20%) ▼|AAPL339.96+4.04 (+1.20%) ▲|ABBV264.10-1.02 (-0.38%) ▼|ABT101.07+0.00 (+0.00%) ▲|ACN177.34-0.07 (-0.04%) ▼|ADBE236.16-2.77 (-1.16%) ▼|AMAT483.81+9.56 (+2.02%) ▲|AMD629.73+0.47 (+0.07%) ▲|AMGN411.56+5.52 (+1.36%) ▲|AMT168.51+1.25 (+0.75%) ▲|AMZN249.96+0.58 (+0.23%) ▲|AVGO352.84+2.48 (+0.71%) ▲|AXP309.33+3.67 (+1.20%) ▲|BA199.65+2.85 (+1.45%) ▲|BAC56.53+0.50 (+0.88%) ▲|BKNG163.15+5.74 (+3.64%) ▲|BLK1,082.04+8.59 (+0.80%) ▲|BMY62.27+0.77 (+1.25%) ▲|BNY149.64-0.55 (-0.37%) ▼|BRK-B505.03-0.15 (-0.03%) ▼|C134.15+2.05 (+1.55%) ▲|CAT816.61+11.36 (+1.41%) ▲|CL85.77+0.45 (+0.53%) ▲|CMCSA21.69-0.44 (-1.99%) ▼|COF200.71+4.10 (+2.08%) ▲|COP127.25-2.09 (-1.62%) ▼|COST920.94+24.46 (+2.73%) ▲|CRM234.66-3.57 (-1.50%) ▼|CSCO107.57+0.60 (+0.56%) ▲|CVS88.03+2.98 (+3.50%) ▲|CVX203.73-1.93 (-0.94%) ▼|DE684.50-10.44 (-1.50%) ▼|DHR223.94+0.17 (+0.08%) ▲|DIS105.48-0.09 (-0.08%) ▼|DUK113.02-0.22 (-0.19%) ▼|EMR158.61+2.47 (+1.58%) ▲|FDX284.36+4.82 (+1.72%) ▲|GD337.60+1.31 (+0.39%) ▲|GE327.10+7.32 (+2.29%) ▲|GEV953.04-2.00 (-0.21%) ▼|GILD149.24-0.45 (-0.30%) ▼|GM82.88+2.31 (+2.87%) ▲|GOOG340.78+1.77 (+0.52%) ▲|GOOGL343.94+1.58 (+0.46%) ▲|GS930.99+7.70 (+0.83%) ▲|HD294.34+2.16 (+0.74%) ▲|HON212.37+0.58 (+0.27%) ▲|IBM226.56-0.50 (-0.22%) ▼|INTC124.44-2.95 (-2.32%) ▼|INTU275.79-1.34 (-0.48%) ▼|ISRG402.44+2.92 (+0.73%) ▲|JNJ269.82-0.86 (-0.32%) ▼|JPM341.75+3.19 (+0.94%) ▲|KO87.99-0.11 (-0.12%) ▼|LIN469.20+1.06 (+0.23%) ▲|LLY1,172.43-9.46 (-0.80%) ▼|LMT517.46-6.24 (-1.19%) ▼|LOW189.01+0.52 (+0.28%) ▲|LRCX314.70+7.54 (+2.45%) ▲|MA567.68+1.60 (+0.28%) ▲|MCD237.35+0.33 (+0.14%) ▲|MDLZ60.20-0.67 (-1.09%) ▼|MDT88.38+0.59 (+0.67%) ▲|META750.89-26.70 (-3.43%) ▼|MMM169.83+2.31 (+1.38%) ▲|MO68.66-0.22 (-0.32%) ▼|MRK148.23+0.25 (+0.17%) ▲|MS196.44+0.12 (+0.06%) ▲|MSFT516.65+18.72 (+3.76%) ▲|MU1,082.86+2.33 (+0.22%) ▲|NEE75.94+0.32 (+0.42%) ▲|NFLX71.12-0.61 (-0.84%) ▼|NKE35.90-0.10 (-0.26%) ▼|NOW136.77-1.01 (-0.73%) ▼|NVDA224.82+0.24 (+0.11%) ▲|ORCL138.45-1.10 (-0.78%) ▼|PEP128.17+0.02 (+0.02%) ▲|PFE28.39-0.03 (-0.09%) ▼|PG145.83+0.15 (+0.10%) ▲|PLTR191.89-0.70 (-0.36%) ▼|PM189.20-2.30 (-1.20%) ▼|QCOM204.75+10.49 (+5.40%) ▲|RTX188.32-0.29 (-0.15%) ▼|SBUX94.35+0.70 (+0.74%) ▲|SCHW99.77+0.28 (+0.28%) ▲|SO82.66-0.23 (-0.28%) ▼|SPG205.18+0.48 (+0.23%) ▲|T25.32-0.13 (-0.50%) ▼|TMO670.32-8.07 (-1.19%) ▼|TMUS166.22+0.87 (+0.53%) ▲|TSLA373.23-4.71 (-1.25%) ▼|TXN277.00+6.35 (+2.35%) ▲|UBER69.19-0.03 (-0.04%) ▼|UNH377.15+2.14 (+0.57%) ▲|UNP273.40-0.68 (-0.25%) ▼|UPS93.03+0.98 (+1.06%) ▲|USB59.32+0.92 (+1.58%) ▲|V367.57-0.42 (-0.11%) ▼|VZ46.95-0.38 (-0.79%) ▼|WFC82.67+0.49 (+0.60%) ▲|WMT107.93+0.34 (+0.32%) ▲|XOM160.19-1.95 (-1.20%) ▼|
20.7 C
New York
Friday, September 25, 2026

Tag: business

newssourceFORcompanyinformationcontent1releasesmarket

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results

ALMATY, Kazakhstan, June 15, 2025 /PRNewswire/ -- Freedom Holding Corp. (NASDAQ: FRHC), the diversified financial group with operations spanning 22 countries, today reported financial...

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DoubleVerify

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In DoubleVerify To Contact Him Directly To...

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Fortrea Holdings

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To...

Backblaze Investor News: If You Have Suffered Losses in Backblaze, Inc. (NASDAQ: BLZE), You Are Encouraged to Contact The Rosen Law Firm About Your...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Backblaze, Inc. (NASDAQ: BLZE) resulting from allegations that Backblaze may have issued materially misleading business information to the investing public.

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for...

Media Release

COPENHAGEN, Denmark; June 15, 2025

Eve Air Mobility and Revo Accelerate Urban Air Mobility with $250M Contract

A fleet of up to 50 aircraft and aftermarket services is poised to revolutionize urban transport across Revo's key markets. PARIS, June 15, 2025 /PRNewswire/ -- Eve Air Mobility ("Eve") (NYSE: EVEX) (NYSE: EVEXW) has signed its first binding framework agreement with...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

20 Textile Enterprises from Qingdao Attended AFF in Tokyo, Japan Hand in Hand

TOKYO, June 15, 2025 /PRNewswire/ -- A report from IQingDao: 2025 Asia Fashion Fair (AFF) grandly opened in Tokyo, Japan on June 9. Organized by...

Cheap AI Bots Eye Junior Coders’ Lunch

In 2007, Luke Arrigoni pulled in $63,000 as a junior software developer. Fast forward to today, and AI tools that supposedly churn out better...

GAC GS8 Traveller Edition Grand Launch Across Three Middle Eastern Nations, Strengthening Premium Mobility Market Strategy

RIYADH, Saudi Arabia, AMMAN, Jordan, and ERBIL, Iraq, June 14, 2025 /PRNewswire/ -- Recently, GAC intensified its Middle Eastern market layout: the GS8 Traveller premiered...

Ready Payday Loans offers Emergency Loans for Bad Credit with No Credit Check

LONG BEACH, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- For individuals facing urgent financial needs, Ready Payday Loans offers fast and reliable access to same-day loans online with no credit check. We are happy to announce our new partnership in June 2025 with lenders across the Nation offering Payday Advance Loans. Whether you're managing medical bills, unexpected car repairs, or late rent, borrowers can now apply for payday loans online same day with instant approval—even if their credit history isn’t perfect. Our streamlined platform connects consumers with reputable lenders who prioritize speed, security, and simplicity. Below is a breakdown of the 5 same day loan partnerships available.

Ram Brand Launches ‘Never Stop Being American’ Marketing Campaign, New Brand Ethos ‘Nothing Stops Ram’

"Never Stop Being American" marketing campaign takes off across broadcast and Ram brand's social media channelsCampaign celebrates America, its people, pastimes and traditions, formally...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBusiness

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers